Ardena Group
- Company typePrivate
- Founded2004
- HeadquartersGhent, Belgium
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
Ardena Group firmographics
Firmographics- Name
- Ardena Group
- Legal name
- Ardena Holding NV
- Website
- https://ardena.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Ownership category
- akta.pro rank
Ardena Group industry classification
Industry- Product category
- Pharmaceutical CDMO and Bioanalytical CRO Services
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Miscellaneous Chemical Products (2890)
- akta.pro primary industry
- Small-Molecule API Process Development & Route Scouting (HLAGAHAA)
- akta.pro secondary industries
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Solid-State Chemistry & Preformulation (Polymorph/Crystallization) (HLAGAHAI), Crystallization, Particle Engineering & Micronization Services (HLAGAHAJ), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Ardena Group is headquartered
LocationHeadquarters
- HQ city
- Ghent
- HQ country
- Belgium
- HQ region
- Europe
Offices5 records
Markets served
Ardena Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- CDMO Services - Drug Product Development: Contract development and manufacturing services for drug products including formulation development, GMP manufacturing, and clinical trial supply
- CDMO Services - Drug Substance Manufacturing: API manufacturing services including HPAPI, PROTACs, and specialized synthesis
- Bioanalytical CRO Services: Contract research services for bioanalysis including biomarker analysis, immunogenicity testing, and clinical trial services
- Nanomedicine Development: Specialized nanoparticle formulation and manufacturing services for precision medicine applications
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Ardena Group product offering
Product offeringCore offering
Ardena Group is an integrated Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) providing end-to-end pharmaceutical development services for complex molecules. Its offerings span four core service areas: Drug Product Development (oral solids, injectables, bioavailability enhancement via spray drying and hot melt extrusion), Nanomedicine Development (lipid, polymeric, and metal nanoparticles, ADCs/XDCs), Bioanalysis Services (biomarkers, immunogenicity, flow cytometry, qPCR, clinical trial services), and Drug Substance Services (PROTACs, molecular glues, solid state research, HPAPI manufacturing).
Product overview
Ardena is an integrated CDMO (Contract Development and Manufacturing Organisation) and bioanalytical CRO that specializes in complex drug development services. The company operates a unified platform combining four core service areas: Drug Product Development (covering oral solids, injectables, bioavailability enhancement via spray drying and hot melt extrusion, and clinical trial supply), Nanomedicine Development (lipid nanoparticles, polymeric nanoparticles, metal nanoparticles, ADCs/XDCs), Bioanalysis Services (biomarkers, immunogenicity, flow cytometry, qPCR), and Drug Substance Services (PROTACs, molecular glues, solid state research, HPAPI). The company has five manufacturing facilities across Europe and the US, offering end-to-end services from early development through GMP manufacturing.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Product Development End-to-end drug product development for small molecules with complex profiles, including poorly soluble compounds, highly potent APIs, controlled substances, and challenging physicochemical characteristics. Covers oral and injectable formulations, process chemistry, scale-up, and GMP manufacturing.
- Nanomedicine Development Comprehensive nanomedicine platform covering lipid nanoparticles, polymeric nanoparticles, liposomes, nanosuspensions, and metal nanoparticles. Spans building block synthesis through GMP production and regulatory submission for nanoparticle-based therapeutics including ADCs and XDCs.
- Bioanalysis Services Full-range bioanalytical services from drug discovery research to phase IV clinical studies. Specializes in analyzing small molecules, proteins, vaccines, biomarkers, immunogenicity, flow cytometry, qPCR, and ADC/XDC PK panels.
- Drug Substance Services Drug substance development covering PROTACs, glues and conjugates, solid state research including polymorph and salt screening, and high potency API (HPAPI) manufacturing capabilities with OEB 3-5 containment for cytotoxic oncology agents.
- Bioavailability Enhancement Technologies including spray drying and hot melt extrusion (HME) for amorphous solid dispersions (ASD) to enhance bioavailability of poorly soluble drugs.
- Clinical Trial Supply Clinical supply services including manufacturing, labeling, packaging, and distribution of clinical trial materials.
Companies that use Ardena Group
Customer profileSegments2 records
Ideal customer profiles2 records
Ardena Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Ardena Group partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Nanologica ABminorArdena divested its drug substance (API) site in Södertälje, Sweden to Nanologica AB. As part of the agreement, Ardena becomes a shareholder in Nanologica and CEO Jeremie Trochu joined Nanologica's Board of Directors.
- CatalentcoreAcquired Catalent's oral solids development and small-scale manufacturing facility in Somerset, New Jersey in February 2025. This strategic acquisition established Ardena's first US site and opened the door to North American bioanalytical services.
- SuanfarmaminorAcquired Idifarma from Suanfarma as part of strategic expansion into Southern Europe. Idifarma was originally sold by Suanfarma to enable Ardena's growth in the Spanish market.
Scale indicators6 records
Recent moves8 records
Expansion highlights6 records
Ardena Group competitors and assessment
Company assessmentBroad incumbents
- Catalent: Global CDMO offering drug product, drug substance, biologics, and clinical supply services across softgel, oral, sterile, and inhalation modalities. Direct competitor across Ardena's drug-product and HPAPI capabilities, and source of Ardena's recently acquired Somerset, NJ facility.
- Eurofins Scientific: Global bioanalytical and pharmaceutical testing services provider with extensive central-lab and biomarker capabilities. Directly comparable to Ardena's Bioanalysis division across PK/PD, immunogenicity, and biomarker assays.
- Lonza Group: Swiss-listed global CDMO leader across small molecules, biologics, cell and gene therapies, and drug product. Comparable in drug-substance, HPAPI, and complex-molecule services, though significantly larger and broader than Ardena.
- Thermo Fisher Scientific (Patheon): Patheon division of Thermo Fisher offers global drug product, API, and clinical trial services. Competes head-to-head on complex small molecules, sterile fill-finish, and bioavailability enhancement, with significantly greater scale and commercial reach.
Direct peers
- Aenova Group: BC Partners-owned European CDMO providing solid dosage forms, sterile liquids, and semi-solids with HPAPI capability. Comparable in PE-backed scale, European footprint, and oral-solid / softgel service mix.
- Cambrex: Permira-owned CDMO providing small-molecule API development, manufacturing, and drug-product services including HPAPI and controlled substances. Highly comparable in drug-substance focus, HPAPI specialization, and PE-backed mid-market position.
- Recipharm: EQT-owned European CDMO focused on oral solids, sterile injectables, APIs, and bioavailability enhancement. Closely comparable in service mix, customer base (small-to-mid pharma and biotech), and PE-backed mid-market positioning.
- PCI Pharma Services: PE-backed global CDMO specializing in clinical trial supply, commercial manufacturing, sterile injectables, and oral solid dose. Comparable in PE-owned mid-market CDMO positioning and integrated drug-product services.
- Vetter Pharma: Family-owned European CDMO specializing in aseptic fill-finish of sterile injectables and complex parenteral formulations. Comparable in high-complexity, regulated drug-product CDMO services and mid-to-large pharma customer base.
- BioAgilytix Labs: PE-backed bioanalytical CRO specializing in large-molecule PK, immunogenicity, and biomarker services for biologics and gene therapies. Closely comparable to Ardena's Bioanalysis division in customer base, services, and PE-owned mid-market positioning.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Ardena Group social profiles
Digital presenceArdena Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ardena Group leadership team
Management profileNumber of profiles
Profiles9 records
Ardena Group subsidiaries and ownership
Company hierarchySubsidiaries5 records
Ardena Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ardena Group M&A and investment
M&A and investmentM&A5 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ardena Group
What does Ardena Group do?
Ardena Group is an integrated Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) providing end-to-end pharmaceutical development services for complex molecules. Its offerings span four core service areas: Drug Product Development (oral solids, injectables, bioavailability enhancement via spray drying and hot melt extrusion), Nanomedicine Development (lipid, polymeric, and metal nanoparticles, ADCs/XDCs), Bioanalysis Services (biomarkers, immunogenicity, flow cytometry, qPCR, clinical trial services), and Drug Substance Services (PROTACs, molecular glues, solid state research, HPAPI manufacturing).
Is Ardena Group a public or private company?
Ardena Group is a private company. It is classified as private equity controlled and is currently operating.
When was Ardena Group founded?
Ardena Group was founded in 2004. It employs 501 to 1,000 people.
Where is Ardena Group based?
Ardena Group is headquartered in Ghent, Belgium, in the Europe region.
How does Ardena Group make money?
Four revenue lines are on record. CDMO Services - Drug Product Development is the primary driver. The others are CDMO Services - Drug Substance Manufacturing, bioanalytical CRO Services and nanomedicine Development.
Who are Ardena Group's main competitors?
Broad incumbents on record are Catalent, Eurofins Scientific, Lonza Group and Thermo Fisher Scientific (Patheon). Direct peers are Aenova Group, Cambrex, Recipharm, PCI Pharma Services, Vetter Pharma and BioAgilytix Labs.
Does Ardena Group have an API?
No public API is recorded for Ardena Group.
What industry is Ardena Group in?
Ardena Group's product category is Pharmaceutical CDMO and Bioanalytical CRO Services. Its primary akta.pro industry code is HLAGAHAA, Small-Molecule API Process Development & Route Scouting, with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 3254 and its SIC code is 2834.